Literature DB >> 27815000

Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.

Wenshi Wang1, Mohamad S Hakim2, Vidya P Nair3, Petra E de Ruiter4, Fen Huang5, Dave Sprengers1, Luc J W Van Der Laan4, Maikel P Peppelenbosch1, Milan Surjit3, Qiuwei Pan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27815000     DOI： 10.1053/j.gastro.2016.09.061

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  10 in total

Review 1.  Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

Authors:  Nassim Kamar; Sven Pischke
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

2.  Antiviral Candidates for Treating Hepatitis E Virus Infection.

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Subhash G Vasudevan; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.

Authors:  Saumya Anang; Nidhi Kaushik; Smita Hingane; Anita Kumari; Jyoti Gupta; Shailendra Asthana; Baibaswata Nayak; C T Ranjith-Kumar; Milan Surjit
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 4.  Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of in vitro and in vivo Evidence.

Authors:  Temi Lampejo
Journal:  J Clin Exp Hepatol       Date:  2022-02-22

5.  Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice.

Authors:  Martijn D B van de Garde; Suzan D Pas; Gertine W van Oord; Lucio Gama; Youkyung Choi; Robert A de Man; Andre Boonstra; Thomas Vanwolleghem
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

6.  Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin.

Authors:  Changbo Qu; Lei Xu; Yuebang Yin; Maikel P Peppelenbosch; Qiuwei Pan; Wenshi Wang
Journal:  Arch Virol       Date:  2017-06-16       Impact factor: 2.574

7.  BALB/c Mouse Is a Potential Animal Model System for Studying Acute and Chronic Genotype 4 Hepatitis E Virus Infection.

Authors:  Yunlong Li; Feiyan Long; Chenchen Yang; Xianhui Hao; Jian Wu; Jianwen Situ; Shuangfeng Chen; Zhongyao Qian; Fen Huang; Wenhai Yu
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

Review 8.  Hepatitis E Virus Drug Development.

Authors:  Volker Kinast; Thomas L Burkard; Daniel Todt; Eike Steinmann
Journal:  Viruses       Date:  2019-05-28       Impact factor: 5.048

9.  Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.

Authors:  Hossein Khalili; Anahid Nourian; Zahra Ahmadinejad; Hamid Emadi Kouchak; Sirous Jafari; Sayed Ali Dehghan Manshadi; Mehrnaz Rasolinejad; Abbas Kebriaeezadeh
Journal:  Acta Biomed       Date:  2020-11-10

Review 10.  Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus.

Authors:  Saumya Anang; Nidhi Kaushik; Milan Surjit
Journal:  J Clin Transl Hepatol       Date:  2018-06-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.